title: Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients

summary: The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease [AD]) in frontotemporal dementia patients after a one-year treatment.

ReferenceCitation: Boutoleau-Bretonnière C, Lebouvier T, Volteau C, Jaulin P, Lacomblez L, Damier P, Thomas-Anterion C, Vercelletto M. Prospective evaluation of behavioral scales in the behavioral variant of frontotemporal dementia. Dement Geriatr Cogn Disord. 2012;34(2):75-82. Epub 2012 Aug 23.

ReferenceCitation: Vercelletto M, Boutoleau-Bretonnière C, Volteau C, Puel M, Auriacombe S, Sarazin M, Michel BF, Couratier P, Thomas-Antérion C, Verpillat P, Gabelle A, Golfier V, Cerato E, Lacomblez L; French research network on Frontotemporal dementia. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23(4):749-59. doi: 10.3233/JAD-2010-101632.

name: CMRR, Centre d'investigation Clinique (CIC), Clinique Neurologique, Hôpital R et G Laënnec, Boulevard Jacques Monod, Nantes, France

family: Vercelletto

full_name: Martine Vercelletto

given: Martine

family: Boutoleau-Bretonnière

full_name: Claire Boutoleau-Bretonnière

given: Claire

name: Plateforme de Biométrie, CPRC CHU de Nantes, Nantes, France

family: Volteau

full_name: Christelle Volteau

given: Christelle

name: CMRR de Toulouse, Clinique Neurologique, Hôpital Purpan, Place du Dr Baylac, Toulouse, France

family: Puel

full_name: Michèle Puel

given: Michèle

name: CMRR de Bordeaux, Clinique Neurologique, Hôpital Pellegrin, Place A Raba Léon, Bordeaux, France

family: Auriacombe

full_name: Sophie Auriacombe

given: Sophie

name: CMRR Ile de France, Service de Neurologie, Hôpital de la Salpêtrière, 47–48 Boulevard de l'Hôpital, Paris, France

family: Sarazin

full_name: Marie Sarazin

given: Marie

name: Unité de Neurologie, Hôpital Sainte-Marguerite, Marseille, France

family: Michel

full_name: Bernard-François Michel

given: Bernard-François

name: CMRR de Limoges, Service de Neurologie, Hôpital Dupuytren, 2 Rue Martin Luther King, Limoges, France

family: Couratier

full_name: Philippe Couratier

given: Philippe

name: CMRR de Saint Etienne, Clinique Neurologique, Hôpital Bellevue, 25 Boulevard Pasteur, Saint-Etienne, France

family: Thomas-Antérion

full_name: Catherine Thomas-Antérion

given: Catherine

name: INSERM U 679, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, Paris, France

family: Verpillat

full_name: Patrice Verpillat

given: Patrice

name: CMRR de Montpellier, Hôpital Gui de Chauliac, 80 Avenue A Fliche, 5 Montpellier Cedex, France

family: Gabelle

full_name: Audrey Gabelle

given: Audrey

name: CMRR de Rennes, Hôpital Pontchaillou, 2 Rue Henri Le Guillou, Rennes, France

family: Golfier

full_name: Véronique Golfier

given: Véronique

family: Cerato

full_name: Evelyne Cerato

given: Evelyne

name: Fédération des Maladies du Système Nerveux, APHP Hôpital de la Salpêtrière; UPMC Paris VI, Pharmacologie; INSERM U 678, 47–48 Boulevard de l'Hôpital, Paris, France

family: Lacomblez

full_name: Lucette Lacomblez

given: Lucette

journal_name: Journal of Alzheimer's Disease

oa_host_type: publisher

evidence: open (via free pdf)

publisher: IOS Press

publisher_dissemination: IOS Press

publisher_group: IOS Press

publisher_normalized: IOS Press

title: Memantine in Behavioral Variant Frontotemporal Dementia: Negative Results

lead_sponsor: Nantes University Hospital


title: Double-Blind, Placebo Controlled Randomized Study of Co-Administering Testosterone With PDE5 Inhibitors in Patients Non-Responders to PDE5 Inhibitors Alone

summary: 30 to 50% of the patients presenting with Erectile Dysfunction (ED) do not respond to PDE V Inhibitor therapy, which is presently considered as the first choice treatment for most ED patients. Recent reports stated a high prevalence of low serum testosterone levels in such non responders, and an improvement of their response by combining testosterone therapy with the PDE V Inhibitor. This suggests there may be a minimum threshold level of blood testosterone for a full effectiveness of PDE V Inhibitor therapy. Two double blind, placebo controlled studies have added support to this hypothesis but one involved only 20 patients while in the other the benefit of combining testosterone was transient. This is a multi-centric study, double blind placebo controlled and randomized as concerns testosterone administration, that aims to objectively assess the efficacy of co-administering testosterone with the PDE 5 inhibitor Tadalafil to improve the erectile function of a large group of ED patients non-responders to PDE V inhibitors alone. Patients will be screened to ensure inclusion and exclusion criteria completion, including a serum testosterone level < 4 ng/ml for total testosterone or < 1 ng/ ml for bioavailable testosterone. They will then enter a four week run-in period in the meanwhile they will receive Tadalafil 10 mg only, once daily, in order to confirm their non responsiveness to PDE V inhibitors and their eligibility to enter the treatment phase based on IIEF scoring, SEP diaries and a Global Assessment Question (GAQ). The patients still non responders after 4 weeks of Tadalafil 10 mg daily will enter a 12 weeks treatment phase including visits at weeks 4, 8, 12 and 16. Treatment procedure will include: 1. continuation of Tadalafil at 10 mg dose daily followed by routine assessment using SEP diaries, IIEF scoring, GAQ and Aging Male Symptoms scale administered at each study visit. Safety assessments will be performed in addition during the last visit (physical examination including DRE, PSA and BCC). 2. Randomization in 2 parallel arms (Placebo gel + Tadalafil 10 mg daily, and Testosterone gel 50 mg + Tadalafil 10 mg daily). If indicated according to suboptimal clinical response of the patient, the dose of study medication will be increased at the 8 or 12 weeks visit to 100mg of testosterone or to 2 sachets of placebo gel. Up to 430 patients will be screened in order that 172 are enrolled in the double blind treatment phase.

status: Completed

study_completion_date_type: Actual

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Actual

lead_sponsor: SELARL du Dr Jacques BUVAT

intervention_type: Other

lead_sponsor_type: industriel

status_simplified: Completed


title: Diagnostic Yield of Esophageal High Resolution Manometry in Patients With Unexplained Dysphagia

summary: Two to 15% of subjects present dysphagia. In case of normal eso-gastro-duodenal endoscopy, patients with dysphagia are referred for esophageal motility testing. Esophageal manometry is the gold standard to evaluate esophageal motility in absence of esophageal obstruction. Two different techniques are available: the conventional manometry and the high resolution manometry. The second one may improve the diagnostic yield and the tolerance of examination in patients with dysphagia.

primary_purpose: Diagnostic

ReferenceType: derived

ReferenceCitation: Roman S, Huot L, Zerbib F, Bruley des Varannes S, Gourcerol G, Coffin B, Ropert A, Roux A, Mion F. High-Resolution Manometry Improves the Diagnosis of Esophageal Motility Disorders in Patients With Dysphagia: A Randomized Multicenter Study. Am J Gastroenterol. 2016 Mar;111(3):372-80. doi: 10.1038/ajg.2016.1. Epub 2016 Feb 2.

family: Roman

full_name: Sabine Roman

given: Sabine

sequence: first

family: Huot

full_name: Laure Huot

given: Laure

sequence: additional

family: Zerbib

full_name: Frank Zerbib

given: Frank

family: des Varannes

full_name: Stanislas Bruley des Varannes

given: Stanislas Bruley

family: Gourcerol

full_name: Guillaume Gourcerol

given: Guillaume

family: Coffin

full_name: Benoit Coffin

given: Benoit

family: Ropert

full_name: Alain Ropert

given: Alain

family: Roux

full_name: Adeline Roux

given: Adeline

family: Mion

full_name: François Mion

given: François

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: American Journal of Gastroenterology

publisher: Ovid Technologies (Wolters Kluwer Health)

publisher_dissemination: Wolters Kluwer Health

publisher_group: Wolters Kluwer Health

publisher_normalized: Wolters Kluwer Health

lead_sponsor: Hospices Civils de Lyon

location_facility: Unité d'Exploration Fonctionnelle Digestive - Hopital Edouard Herriot - 69437 LYON Cedex 03

intervention_type: Device

lead_sponsor_type: academique


title: Sleep and Appetite Measures as Suicidal Risk Factors in a French- Spanish Cohort of Suicidal Patients.

acronym: SmartCriseS

summary:
Sleep and appetite disorders as well as social exclusion, have been linked to the emergence of suicidal ideation (SI) and suicide attempts.This study aims to evaluate the relationship between those factors and suicidal ideation and behaviour. To assess those factors an ecological momentary assessment (EMA) desing will be used.

EMA will be carried out using 2 applications integrated into the smartphone of participants (Android or iOS), one to make an explicit data collection with questions and another one for the implicit collection of data from mobile sensors.

1044 suicide attempters will be included in three sites and followed for 6 months. Participants will be evaluated at inclusion and at the end of follow-up. The hypothesis is that sleep, appetite and social exclusion factors collected with the smartphone application will be linked to the intensity of death wish, suicidal ideations and suicidal attempts.

An auxiliary study will also be led with 300 patients carrying an actimeter for the 30 first days after inclusion. This will help collecting more accurate data on various sleep parameters.

study_start_date_type: Actual

status: Recruiting

study_completion_date_type: Anticipated

primary_purpose: Prevention

enrollment_type: Anticipated

ReferenceCitation: Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev. 2021 Apr 22;4:CD013668. doi: 10.1002/14651858.CD013668.pub2.

name: Centre for Youth Mental Health; The University of Melbourne; Melbourne Australia

family: Witt

full_name: Katrina G Witt

given: Katrina G

name: Department of Psychological Medicine, Faculty of Medical and Health Sciences; The University of Auckland; Auckland New Zealand

family: Hetrick

full_name: Sarah E Hetrick

given: Sarah E

family: Rajaram

full_name: Gowri Rajaram

given: Gowri

name: Speciality of Psychiatry; University of Sydney School of Medicine; Sydney Australia

family: Hazell

full_name: Philip Hazell

given: Philip

name: Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience; King's College London; London UK

family: Taylor Salisbury

full_name: Tatiana L Taylor Salisbury

given: Tatiana L

name: Self-Harm Research Group, School of Psychology; University of Nottingham; Nottingham UK

family: Townsend

full_name: Ellen Townsend

given: Ellen

name: Centre for Suicide Research, Department of Psychiatry; University of Oxford; Oxford UK

family: Hawton

full_name: Keith Hawton

given: Keith

journal_name: Cochrane Database of Systematic Reviews

oa_host_type: repository

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

license_normalized: no license

repository_normalized: University of Melbourne - Minerva Access

version: publishedVersion

evidence: oa repository (via OAI-PMH title and first author match)

license: cc-by

license_normalized: cc-by

repository_institution: University of Nottingham - Repository@Nottingham

repository_institution: University of Oxford - Oxford University Research Archive (ORA)

repository_institution: University of Bristol - Bristol Research

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

ReferenceCitation: Berrouiguet S, Barrigón ML, Castroman JL, Courtet P, Artés-Rodríguez A, Baca-García E. Combining mobile-health (mHealth) and artificial intelligence (AI) methods to avoid suicide attempts: the Smartcrises study protocol. BMC Psychiatry. 2019 Sep 7;19(1):277. doi: 10.1186/s12888-019-2260-y.

family: Berrouiguet

full_name: Sofian Berrouiguet

given: Sofian

family: Barrigón

full_name: María Luisa Barrigón

given: María Luisa

family: Castroman

full_name: Jorge Lopez Castroman

given: Jorge Lopez

family: Courtet

full_name: Philippe Courtet

family: Artés-Rodríguez

full_name: Antonio Artés-Rodríguez

given: Antonio

family: Baca-García

full_name: Enrique Baca-García

given: Enrique

currency_apc_doaj: GBP

journal_name: BMC Psychiatry

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

host_type: publisher

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

repository_institution: Universidad Autónoma de Madrid - Biblos-e Archivo

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

location_facility:
CHU Montpellier
Fundacion Jimenez Diaz Hospital


type: Registry Identifier

title: Effects of a Long-term and Regular Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism : a Cross-over Designed Study to Determine the Specific Role of Naringin

summary:
Epidemiological studies definitively show that fruit and vegetable consumption is an important factor for the prevention of age-related diseases such as cardiovascular diseases (CVD) and osteoporosis. Citrus fruits are among the fruits which are the most frequently consumed worldwide, essentially as juices.

Citrus fruits are the exclusive sources of a particular class of dietary flavonoids, namely flavanones. Grapefruit consumed as whole fruit or juice corresponds to a quantitatively significant source of a specific flavanone called naringin.

ReferenceCitation: Habauzit V, Verny MA, Milenkovic D, Barber-Chamoux N, Mazur A, Dubray C, Morand C. Flavanones protect from arterial stiffness in postmenopausal women consuming grapefruit juice for 6 mo: a randomized, controlled, crossover trial. Am J Clin Nutr. 2015 Jul;102(1):66-74. doi: 10.3945/ajcn.114.104646. Epub 2015 May 27.

family: Habauzit

full_name: Véronique Habauzit

given: Véronique

family: Verny

full_name: Marie-Anne Verny

given: Marie-Anne

family: Milenkovic

full_name: Dragan Milenkovic

given: Dragan

family: Barber-Chamoux

full_name: Nicolas Barber-Chamoux

given: Nicolas

family: Mazur

full_name: Andrzej Mazur

given: Andrzej

family: Dubray

full_name: Claude Dubray

given: Claude

family: Morand

full_name: Christine Morand

given: Christine

journal_name: The American Journal of Clinical Nutrition

evidence: open (via free article)

publisher: Oxford University Press (OUP)

publisher_dissemination: Oxford University Press

publisher_group: Oxford University Press

publisher_normalized: Oxford University Press

lead_sponsor: University Hospital, Clermont-Ferrand

intervention_type: Behavioral


title: Study of Quality of Life After Aneurysmal Subarachnoid Hemorrhage in Patients Aged 70 Years or Older.

acronym: FASHE

summary:
In all the Western populations, the annual incidence of subarachnoid hemorrhage (SAH) increase with age. In patients older than 70 years, the occurrence of SAH exposes them to high risk of morbidity and a poor quality of life.

In this age bracket, the single randomized which compared endovascular coiling to microsurgical clipping (ISAT Study) showed that the relative risk of morbidity increased after coiling. Moreover, some prospectives studies about endovascular coiling described favorable outcome in 48% to 63% of patients, complete occlusion in 51% to 69% and a procedural complication rate in 13% to 19%. From prospectives series, the proportion of favorable outcome after microsurgical clipping was estimated around 66% but the procedural complications are few reported. The outcome for patients treated conservatively was catastrophic. Lastly, the hydrocephalus in this age class is common, occurring in 55% of patients.

The study hypothesis is that, in this age class, no difference exists between the 2 obliteration procedures.

An accurate evaluation of result in term of functional disability, quality of life and prognosis predictive factors seems a judicious question.

study_type: Observational

time_perspective: Prospective

ReferenceType: background

ReferenceCitation: Proust F, Gérardin E, Derrey S, Lesvèque S, Ramos S, Langlois O, Tollard E, Bénichou J, Chassagne P, Clavier E, Fréger P. Interdisciplinary treatment of ruptured cerebral aneurysms in elderly patients. J Neurosurg. 2010 Jun;112(6):1200-7. doi: 10.3171/2009.10.JNS08754.

ReferenceCitation: Proust F, Bracard S, Thines L, Leclerc X, Penchet G, Bergé J, Vignes JR, Irthum B, Gabrillargues J, Chazal J, Bataille B, Drouinau J, Mourier K, Ricolfi F, Gay E, Bessou P, Lonjon M, Sedat J, David P, Lajaunias P, Morandi X, Gauvrit JY, Pelissou I, Turjman F, Roche PH, Dufour H, Levrier O, Emery E, Courthéoux P, Laguarrigue J, Cognard C, Civit T, Lejeune JP. [Aneurismal subarachnoid hemorrhage in the elderly subject. Should this patient participate in a randomized clinical trial?]. Neurochirurgie. 2010 Feb;56(1):67-72. doi: 10.1016/j.neuchi.2009.11.002. Epub 2010 Jan 8. French.

lead_sponsor: University Hospital, Rouen

location_facility:
PROUST
Rouen University Hospital


title: Impact of a Therapeutic Education Program Specifically Adapted to the Precarious People Supported in Therapeutic Coordination Apartments on the Acceptance of Their Disease and the Management of Their Care

acronym: EDUPACT

summary:
Through its patient-centered approach and focus on developing coping skills and coping strategies, Health Education could be an effective approach in therapeutic coordination apartments to reduce the perceived treatment burden among people in precarious situations with one or more chronic diseases. Decreasing perception of burden would improve their quality of life and adherence to treatment.

The general hypothesis explored in this project is that the experience of the disease, the perception of the burden of treatment, the autonomy and the quality of life of the residents improve more importantly in therapeutic coordination apartments having implemented a formalized and structured Health Education approach (experimental group) than in those who did not set up formalized and structured Health Education approach (control group).

status: Unknown status

location_facility:
Act Passerelle
ACT Le Logis Montjoie
Act Aurore
CHU de Nantes
ACT Louis Guilloux
Act Acothe

status_simplified: Unknown


title: Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis

summary:
Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated. Transgenic mice expressing the cleaved form of caspases by Lyn, a tyrosine kinase Src family, develop an inflammatory syndrome with the characteristics of human psoriasis.

To clarify the relationship between the cleaved form of Lyn by caspases and psoriasis, the investigators intend to develop a clinical study to analyze the expression, cleavage and activity of Lyn and the activation of caspases from skin biopsies of patients with this disease.

This study will be conducted on a cohort of patients with different forms of psoriasis (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated with chronic inflammation. Thus, the investigators will evaluate the expression and activity of Lyn from skin lesion (L) and non-lesional (NL) from the same patient in parallel with the level of caspase activation and apoptotic inflammatory.

Thus, the investigators will verify that the cleavage by caspases of Lyn is associated specifically with psoriasis, as the investigators believe, or more generally to the skin inflammation. The investigators work would then define the cleavage by caspases of Lyn as a new potential marker of human psoriasis.

design_allocation: Non-Randomized

primary_purpose: Basic Science

ReferenceCitation: Aira LE, Gonçalves D, Bossowski JP, Rubio-Patiño C, Chiche J, Paul-Bellon R, Mondragón L, Gesson M, Lecucq-Ottavi P, Obba S, Colosetti P, Luciano F, Bailly-Maitre B, Boyer L, Jacquel A, Robert G, Ricci JE, Ortonne JP, Passeron T, Lacour JP, Auberger P, Marchetti S. Caspase 1/11 Deficiency or Pharmacological Inhibition Mitigates Psoriasis-Like Phenotype in Mice. J Invest Dermatol. 2019 Jun;139(6):1306-1317. doi: 10.1016/j.jid.2018.11.031. Epub 2018 Dec 17.

family: Aira

full_name: Lazaro Emilio Aira

given: Lazaro Emilio

family: Gonçalves

full_name: Diogo Gonçalves

given: Diogo

family: Bossowski

full_name: Jozef P. Bossowski

given: Jozef P.

family: Rubio-Patiño

full_name: Camila Rubio-Patiño

given: Camila

family: Chiche

full_name: Johanna Chiche

given: Johanna

family: Paul-Bellon

full_name: Rachel Paul-Bellon

given: Rachel

family: Mondragón

full_name: Laura Mondragón

given: Laura

family: Gesson

full_name: Maéva Gesson

given: Maéva

family: Lecucq-Ottavi

full_name: Priscillia Lecucq-Ottavi

given: Priscillia

family: Obba

full_name: Sandrine Obba

given: Sandrine

family: Colosetti

full_name: Pascal Colosetti

given: Pascal

family: Luciano

full_name: Frédéric Luciano

given: Frédéric

family: Bailly-Maitre

full_name: Béatrice Bailly-Maitre

given: Béatrice

family: Boyer

full_name: Laurent Boyer

given: Laurent

family: Jacquel

full_name: Arnaud Jacquel

given: Arnaud

family: Robert

full_name: Guillaume Robert

given: Guillaume

family: Ricci

full_name: Jean-Ehrland Ricci

given: Jean-Ehrland

family: Ortonne

full_name: Jean-Paul Ortonne

given: Jean-Paul

family: Passeron

full_name: Thierry Passeron

given: Thierry

family: Lacour

full_name: Jean-Philippe Lacour

given: Jean-Philippe

family: Auberger

full_name: Patrick Auberger

given: Patrick

family: Marchetti

full_name: Sandrine Marchetti

journal_name: Journal of Investigative Dermatology

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - uB

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Hospices Civils de Lyon

lead_sponsor: Centre Hospitalier Universitaire de Nice

location_facility: Assistance Publique - Hôpitaux de Marseille


title: Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study

acronym: COCCA

summary: The purpose of this randomized controlled trial is to evaluate the hemodynamic effect of low dose corticosteroid therapy (hydrocortisone and fludrocortisone) in the treatment of adult cardiogenic shock.

ipd_sharing: Undecided

lead_sponsor: CMC Ambroise Paré

location_facility: Hôpitaux Universitaires Pitié Salpêtrière

location_facility: Centre Hospitalier Saint Joseph Saint Luc

location_facility: Centre cardiologique du nord saint denis

location_facility: CH Intercommunal de Villeneuve Saint Georges

intervention_type: Combination Product

status_simplified: Ongoing


title: Biomarker to Predict the Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients: a Transcriptomic Study

acronym: BIOMARK

summary: This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP patients. 25 patients with a diagnosis of CIDP according to European criteria, naïve of treatment, will be included and followed for 1 year. Clinical assessment (RT-MRC ; Martin vigorimeter, RT-mISS,R-ODS,TW25, 9hole-peg test) will be performed at baseline and at 3, 6 and 12 months after the first IVIG course. Responder/No responder status will be defined at 3 month and confirmed at 12 months. Blood samples will be collected before the IVIG course at baseline, and at 2months and 6 months. At the end of the first IVIG course a blood sample will be collected to assess early changes of transcriptome. The CIDP diagnosis and responder/no responder status will be confirmed by an independent committee. The transcriptome of the patients will be individually analyzed and compared regarding Responder/Non responder status to a control groups of 20 healthy subjects

location_facility: Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild

location_facility: Service de Neurologie, CHU de Strasbourg

location_facility: Service de Physiologie Clinique - Explorations Fonctionnelles, Hôpital Lariboisière

location_facility: CHU Nantes, Laboratoire d'explorations fonctionnelles

location_facility: Service de Neurologie Hopital du Kremlin Bicêtre

location_facility: Centre Hospitalier Intercommunal de Poissy/Saint-Germain-en-Laye


ipd_sharing_description: Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared.

lead_sponsor: Assistance Publique - Hôpitaux de Paris

acronym: DiabOUT

location_facility: Centre hospitalier intercommunal de Créteil

location_facility: AP-HP - hôpital européen Georges-Pompidou

location_facility: CH de Saint-Denis - hôpital Delafontaire

ipd_sharing: Yes

type: EudraCT Number

type: Other Grant/Funding Number

source: euctr

title: Extending Time Without Diabetes After Bariatric Surgery: a Randomized Controlled Trial Comparing the Metformin Addition or Not to Standard Care

summary: This study is a randomized trial that evaluates the effect of metformin addition or not to standard care on the duration of diabetes remission after bariatric surgery.


intervention_type: Drug

lead_sponsor: Centre Hospitalier Universitaire de Saint Etienne

location_country: Monaco France

acronym: ROC-SPA

location_facility: CHU Montpellier - 2 - Unité Clinique thérapeutique des Maladies Ostéo-Articulaires

ipd_sharing: No

title: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

summary:
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by inflammatory arthritis and enthesitis involving the spine. AxSpA prevalence is around 0.17% of the French population. Tumor necrosis factor (TNF) was the first target defined in axSpA. Since one third of axSpA patients failed to the first TNF blocker, many axSpA patients received a second biological Disease-Modifying AntiRheumatic Drugs (bDMARDs). Until few months, the only choice was to use a second TNF blocker.Since 2003, pharmaceutical companies investigated efficacy of TNF blockers already used in rheumatoid arthritis. Etanercept is a fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab, infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion between a fab fragment targeting TNF and a Peg fraction. All demonstrated efficacy versus placebo in a randomized double blinded study

In case of failure to the first TNF blockers, rheumatologists will follow the "Treat-to-Target" principle. This approach already demonstrated its benefit in rheumatoid arthritis or in psoriatic arthritis. This concept was also suggested for axSpA with low levels of evidence and recommendation. So rheumatologist will provide the best treatment in case of failure to the first TNF blockers, which is a daily clinical situation. Since few months, rheumatologists have the choice between targeting IL-23/17 axis compared to a second TNF blocker.


title: TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)

summary: The aim is to assess the impact of tranexamic acid (TXA) for preventing postpartum hemorrhage (PPH) following a cesarean section (CS).

ReferenceCitation: Sentilhes L, Sénat MV, Le Lous M, Winer N, Rozenberg P, Kayem G, Verspyck E, Fuchs F, Azria E, Gallot D, Korb D, Desbrière R, Le Ray C, Chauleur C, de Marcillac F, Perrotin F, Parant O, Salomon LJ, Gauchotte E, Bretelle F, Sananès N, Bohec C, Mottet N, Legendre G, Letouzey V, Haddad B, Vardon D, Madar H, Mattuizzi A, Daniel V, Regueme S, Roussillon C, Benard A, Georget A, Darsonval A, Deneux-Tharaux C; Groupe de Recherche en Obstétrique et Gynécologie. Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. N Engl J Med. 2021 Apr 29;384(17):1623-1634. doi: 10.1056/NEJMoa2028788.

name: From the Department of Obstetrics and Gynecology (L.S., H.M., A.M.), the Department of Clinical Research and Innovation (S.R.), and the Euclid–French Clinical Research Infrastructure Network (F-CRIN) Clinical Trials Platform, Department of Clinical Research and Innovation (C.R.), Bordeaux University Hospital, and the Public Health Department, Clinical Epidemiology Unit, Centre Hospitalier Universitaire (CHU) Bordeaux (A.B., A.G.), Bordeaux, the Department of Obstetrics and Gynecology, Bicêtre University...

family: Sentilhes

full_name: Loïc Sentilhes

given: Loïc

family: Sénat

full_name: Marie V. Sénat

given: Marie V.

family: Le Lous

full_name: Maëla Le Lous

given: Maëla

family: Winer

full_name: Norbert Winer

given: Norbert

family: Rozenberg

full_name: Patrick Rozenberg

family: Kayem

full_name: Gilles Kayem

given: Gilles

family: Verspyck

full_name: Eric Verspyck

given: Eric

family: Fuchs

full_name: Florent Fuchs

given: Florent

family: Azria

full_name: Elie Azria

given: Elie

family: Gallot

full_name: Denis Gallot

given: Denis

family: Korb

full_name: Diane Korb

given: Diane

family: Desbrière

full_name: Raoul Desbrière

given: Raoul

family: Le Ray

full_name: Camille Le Ray

given: Camille

family: Chauleur

full_name: Céline Chauleur

given: Céline

family: de Marcillac

full_name: Fanny de Marcillac

given: Fanny

family: Perrotin

full_name: Franck Perrotin

given: Franck

family: Parant

full_name: Olivier Parant

given: Olivier

family: Salomon

full_name: Laurent J. Salomon

given: Laurent J.

family: Gauchotte

full_name: Emilie Gauchotte

given: Emilie

family: Bretelle

full_name: Florence Bretelle

given: Florence

family: Sananès

full_name: Nicolas Sananès

given: Nicolas

family: Bohec

full_name: Caroline Bohec

given: Caroline

family: Mottet

full_name: Nicolas Mottet

ReferenceCitation: Sentilhes L, Daniel V, Deneux-Tharaux C; TRAAP2 Study Group and the Groupe de Recherche en Obstétrique et Gynécologie (GROG). TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. BMC Pregnancy Childbirth. 2020 Jan 31;20(1):63. doi: 10.1186/s12884-019-2718-4.

name: On behalf of the TRAAP2 Study Group and the Groupe de Recherche en Obstétrique et Gynécologie (GROG)

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

title: TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial – a study protocol

location_facility: Hôpital universitaire Necker-Enfants malades

location_facility: Centre Hospitalier Intercommunal de Créteil

location_facility: Centre Hospitalier Intercommunal Poissy-Saint Germain


lead_sponsor: University Hospital, Lille

acronym: FLUNEXT

location_facility: Centre Hospitalier de Versailles - Le Chesnay Rocquencourt

location_facility: Gpe Hosp Cochin Saint Vincent de Paul - Paris

location_facility: Hôpital Edouard Herriot Hospices Civils de Lyon

type: Other Identifier

title: Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.

summary: The aim of this study is to evaluate the possibility to repropose marketed drugs as antiviral ones, based on their ability to reverse the transcriptomic signature of the infected cells. This strategy has to be considered is the context of emerging viral diseases and of increase of resistance to antivirals. Concerning infection by Influenza viruses, the main drugs were identified and evaluated on in vitro and in vivo models: diltiazem. Therefore, it will be assess the efficacy of these the drug, compared to placebo, to treat severe flu.


title: Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial" HYPOREME

acronym: HYPOREME

summary:
Each year, only one third of patients registered on the waiting list receive a kidney transplant. Numerous paths are being explored with the aim of reversing this shortage. The first is to increase the number of organs by developing harvesting from donors in a state of brain-death (BD) termed "expanded criteria donors" or from patients deceased from circulatory arrest.

Another fundamental factor is to insure the success of the transplant by limiting the dysfunction of donor kidneys, marked by a delayed graft function (DFG).

The development of techniques to insure correct perfusion of harvested organs, and the optimization of reanimation and intensive care of brain-dead donors constitute important factors in DGF reduction.

Therapeutic Hypothermia could to be an attractive care strategy for BD patients.

primary_purpose: Other

location_facility:
Hopital Necker
CH La Roche sur Yon
CHU Strasbourg
CH Marne la Vallée (GHEF)
CH Le Mans
CHU d'Angers
CHU Tenon
Hopital Henri Mondor
CHU Poitiers
CH Laval
CHU Montpellier
CH Lorient
CH de Blois
CH Avignon
CH Annecy Genevois
CHRU Lille
CHU Foch
Hopital Saint Louis
CHU de Bordeaux
CHU Reims
CHRU Saint-Etienne
CH Saint Brieuc
CHU Brest
CH Saintes
CH Vannes
CHU Toulouse
CHU Limoges
CHU de Dijon
CHRU Nancy
Hopital de la Pitié Salpetriere
Hopital de la Conception
Chu Clermont Ferrand
CH de Meaux (GHEF)
CH Bourges
CH Orléans
Nantes University Hospital
CH Angouleme
CH La Rochelle
CHU Amiens-Picardie
Ch Cholet
CH Cornouaille
CH de Dreux
CHU Caen
Hopital de la Timone
CH Morlaix
CHU Tours
CHU Grenoble
CHU Nice
CHU de Lyon
CH Saint Nazaire
CHU Rouen
CHU Rennes
Hopital Bicetre
CH Saint Malo

intervention_type: Procedure


title: Advanced Nurses vs. General Practitioners for the Management of Outpatient Alcohol Detoxification: a Randomized Clinical Trial Comparing Safety and Costs

acronym: SAMBA

summary:
The SAMBA study aims to assess the safety and cost comparison of the management of outpatient alcohol detoxification, between an advanced nurse protocol on the one hand (experimental group), and a GP-based treatment on the other hand (standard-of-care group).

In the advanced nurse (AN) group, nurses manage alcohol detox using a predefined protocol based on both the Cushman and CIWA-Ar scales. Depending on the Cushman and CIWA-Ar scores, which are calculated at every consultation, advanced nurse can adjust the diazepam dosing. In case of any serious adverse event or uncontrolled withdrawal complication, an addiction specialist stands in back-up and can be appealed to decide whether the outpatient detox can be continued or whether the patient has to be hospitalized. In the GP group, GPs can manage patients as they wish.

primary_purpose: Health Services Research

location_facility:
CSAPA CHRU - Le PARI
CH Roubaix
CHU Strasbourg
CH Limoux
Csapa Anpaa63
CHU Clermont-Ferrand
Csapa Anpaa66
CHU Nantes
CSAPA La Trame - ANPAA59
CH Boulogne
CH du Rouvray
CHU Créteil
CH Perpignan
CH Troyes
CHU Brest
CH Beziers
Les Apsyades
CH Lens - CSAPA Le Square
CHU Nancy
Centre LOGOS
CH Dunkerque
CSAPA Arc-en-Ciel
CH Alpes-Isère
CHU Grenoble
CH Tourcoing
CHU Rouen


title: The OPTI-AGED Study : Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality in Elderly Patients. A Randomized, Multicentre, Prospective Controlled Study

acronym: OPTI-AGED

summary:
With the increasing aging population demographics and life expectancies, the number of very elderly patients undergoing surgery is rising. Elderly patients constitute an increasingly large proportion of the high-risk surgical group.

Cardiac complications and postoperative pulmonary complications are equally prevalent and contribute similarly to morbidity, mortality, and length of hospital stay. Specific optimization strategy of general anesthesia has been tested in high-risk patients undergoing major surgery to improve outcomes.

Our hypothesis is that a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia may improve short- and long- term outcome in elderly undergoing high risk surgery.

primary_purpose: Supportive Care

ReferenceCitation: Molliex S, Passot S, Futier E, Bonnefoi M, Rancon F, Lemanach Y, Pereira B. Stepped wedge cluster randomised controlled trial to assess the effectiveness of an optimisation strategy for general anaesthesia on postoperative morbidity and mortality in elderly patients (the OPTI-AGED study): a study protocol. BMJ Open. 2018 Jun 19;8(6):e021053. doi: 10.1136/bmjopen-2017-021053.

location_facility:
Chu Rennes
Chu Saint Etienne
Ch Paris Beaujon
Médipôle Lyon - Villeurbanne
Chu Clermont-Ferrand
Chu Marseille Nord
Chu Poitiers
Hopital Central Strasbourg
Hopital Hautepierre Strasbourg
Chu Marseille La Timone
Chu Nimes
CHU NICE
CHU LYON
Chu Grenoble
Lyon Sud - CHU
CHU de Nantes
Chu Rouen
Ch Paris Pitie Salpetriere
Ch Paris Saint Antoine
Chu Montpellier
CHRU Lille - Salengro
CHU Amiens - Picardie
CHU LILLE - Huriez
Ch Paris Bichat
Chu Nancy
CHU CAEN
Chu Dijon
Ch Saint Louis-Lariboisiere
Chu Toulouse


title: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

acronym: VERDICT

summary:
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic and bleeding complications compared to patients with normal renal function. Direct oral anticoagulants (DOAs) have been shown to be at least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate renally impaired patients were poorly represented and patients with severe renal insufficiency not at all. So no dose reduction was considered.

Surprisingly, DOAs have been approved for VTE treatment in moderate and severe renally impaired patients. There is need to evaluate a reduced dose of DOAs for VTE treatment in patients with moderate and severe renal insufficiency.

We plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC in VTE patients with moderate or severe renal insufficiency in terms of net clinical benefit (recurrent VTE and major bleeding) at 3 months.

location_facility: Hôpital Charles Foix - APHP Ivry sur Seine


acronym: PEAGE

location_facility: Hôpitaux Universitaires Louis Mourier Paris Nord

location_facility: Centre Hospitalier Intercommunal Toulon La Seyne sur Mer

title: Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE

summary:
The treatment of the venous thromboembolic disease, including pulmonary embolism (PE), is based on anticoagulants. During the last decade, all the randomized clinical trials evaluating these anticoagulants have included PE patients with an average age below 60 years. But in clinical pratice, approximately 50% of PE patients are older than 75 years.

So the investigators want to perform a french multicentre prospective cohort of consecutive patients receiving an anticoagulant treatment for a symptomatic and confirmed PE. All the validated and available anticoagulant treatments are authorized in this cohort (unfractionnated and low molecular weight heparins, fondaparinux, vitamin K antagonists and direct oral anticoagulants).

This cohort will provide data regarding the bleeding risk and the risk of PE recurrences and regarding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of these anticoagulants in this older population. Using population approach modelling , the investigators will pay particular attention to the sources of PK/PD variability PK / PD such as genetic polymorphisms of P-glycoprotein and cytochrome P450.

Using all these data , the investigators will try to identify significant risk factors for bleeding and venous thromboembolic events.


title: Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis

acronym: AntibioCor

summary:
Treatment of reference of severe alcoholic hepatitis is based on corticosteroids, given for 28 days. However, about 25-35% of patients do not take benefit from this treatment and die within the 6 months following the diagnosis. Numerous trials have evaluated the impact of several strategies in association with corticosteroids. None of them has shown an improvement in survival (primary endpoint) as compared to corticosteroids alone.

The project is based on an approach never tested in a randomized controlled trial in severe alcoholic hepatitis, targeting the group of patients at high risk of death (25-35% at 2 months). This approach is based on animal and human studies.Antibiotics are effective in animal models and in other circumstances characterized by liver failure such as gastrointestinal bleeding related to portal hypertension. The interest of studying this population is emphasized by the frequency of infections in these critically ill patients. Antibiotics will be administered before the development of any infection, as it is likely that these patients present with mesenteric bacterial adenitis without systemic signs of infection. Primary endpoint will be 2-month survival as most deaths occur within 60 days and treatment is given for 30 days.

ReferenceCitation: Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. doi: 10.1136/gut.2010.224097. Epub 2010 Oct 12.

ReferenceCitation: Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214.

family: Nguyen-Khac

full_name: Eric Nguyen-Khac

family: Thevenot

full_name: Thierry Thevenot

given: Thierry

family: Piquet

full_name: Marie-Astrid Piquet

given: Marie-Astrid

family: Benferhat

full_name: Saïd Benferhat

given: Saïd

family: Goria

full_name: Odile Goria

given: Odile

family: Chatelain

full_name: Denis Chatelain

family: Tramier

full_name: Blaise Tramier

given: Blaise

family: Dewaele

full_name: François Dewaele

given: François

family: Ghrib

full_name: Salah Ghrib

given: Salah

family: Rudler

full_name: Marika Rudler

given: Marika

family: Carbonell

full_name: Nicolas Carbonell

family: Tossou

full_name: Hervé Tossou

given: Hervé

family: Bental

full_name: Abdeslam Bental

given: Abdeslam

family: Bernard-Chabert

full_name: Brigitte Bernard-Chabert

given: Brigitte

family: Dupas

full_name: Jean-Louis Dupas

given: Jean-Louis

journal_name: New England Journal of Medicine

publisher: Massachusetts Medical Society

publisher_dissemination: Massachusetts Medical Society

publisher_group: Massachusetts Medical Society

publisher_normalized: Massachusetts Medical Society

title: Glucocorticoids plusN-Acetylcysteine in Severe Alcoholic Hepatitis

ReferenceCitation: Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review.

family: Lucey

full_name: Michael R. Lucey

given: Michael R.

family: Mathurin

full_name: Philippe Mathurin

given: Philippe

family: Morgan

full_name: Timothy R. Morgan

given: Timothy R.

title: Alcoholic Hepatitis

ReferenceCitation: Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13.

title: Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor

ReferenceCitation: Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.

ReferenceCitation: Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013 Sep 11;310(10):1033-41. doi: 10.1001/jama.2013.276300.

title: Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis

location_facility:
CHU de Caen
Hôpital La Pitié (AP-HP)
Centre Hospitalier
Hôpital Jean Verdier (AH-HP)
CHU d'Amiens
CHU Poitiers
CHU Pontchaillou
Hôpital Claude Huriez, CHU
Hôpital Saint Antoine (AP-HP)
Hôpital Paul Brousse (AH-HP)
CHU Montpellier
CHU Grenoble
CHU Nantes
Hôpital BEaujon (AP-HP)
CHU Nice
CHU
Centre hospitalier
CHU de Besançon


title: Controlled Education Of Patients After Stroke

acronym: CEOPS

summary: The main objective of the study is to compare the benefit of optimised follow-up by nursing personnel from the vascular neurology department, including therapeutic follow-up and an educational program directed to the patient and a caregiving member of his social circle, with that of a typical follow-up.

ReferenceCitation: Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021 Nov 23;11:CD001919. doi: 10.1002/14651858.CD001919.pub4. Review.

name: Academic Unit for Ageing and Stroke Research; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust; Bradford UK

family: Crocker

full_name: Thomas F Crocker

given: Thomas F

family: Brown

full_name: Lesley Brown

given: Lesley

family: Lam

full_name: Natalie Lam

given: Natalie

name: Academic Unit for Ageing and Stroke Research; University of Leeds; Bradford UK

family: Wray

full_name: Faye Wray

given: Faye

name: Department of Health Sciences; University of York and the Hull York Medical School; York UK

family: Knapp

full_name: Peter Knapp

given: Peter

family: Forster

full_name: Anne Forster

given: Anne

ReferenceCitation: Mendyk AM, Duhamel A, Bejot Y, Leys D, Derex L, Dereeper O, Detante O, Garcia PY, Godefroy O, Montoro FM, Neau JP, Richard S, Rosolacci T, Sibon I, Sablot D, Timsit S, Zuber M, Cordonnier C, Bordet R; on the behalf of Strokavenir network. Controlled Education of patients after Stroke (CEOPS)- nurse-led multimodal and long-term interventional program involving a patient's caregiver to optimize secondary prevention of stroke: study protocol for a randomized controlled trial. Trials. 2018 Feb 22;19(1):137. doi: 10.1186/s13063-018-2483-0.

apc_source: openAPC

family: Mendyk

full_name: Anne-Marie Mendyk

given: Anne-Marie

family: Duhamel

full_name: Alain Duhamel

given: Alain

family: Bejot

full_name: Yannick Bejot

given: Yannick

family: Leys

full_name: Didier Leys

given: Didier

family: Derex

full_name: Laurent Derex

given: Laurent

family: Dereeper

full_name: Olivier Dereeper

given: Olivier

family: Detante

full_name: Olivier Detante

family: Garcia

full_name: Pierre-Yves Garcia

given: Pierre-Yves

family: Godefroy

full_name: Olivier Godefroy

family: Montoro

full_name: Francisco Macian Montoro

given: Francisco Macian

family: Neau

full_name: Jean-Philippe Neau

given: Jean-Philippe

family: Richard

full_name: Sébastien Richard

given: Sébastien

family: Rosolacci

full_name: Thierry Rosolacci

family: Sibon

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Grenoble Ecole de Management

repository_institution: Université de Lille (University Of Lille) - LillOA

repositories:
HAL
LillOA (Lille Open Archive)
PubMed Central

title: Controlled Education of patients after Stroke (CEOPS)- nurse-led multimodal and long-term interventional program involving a patient’s caregiver to optimize secondary prevention of stroke: study protocol for a randomized controlled trial

location_facility: Ch Intercommunal Compiègne-Noyon - Compiegne


title: A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

acronym: SARAH

summary: The purpose of this study is to determine whether RADIOEMBOLIZATION with 90 Yttrium microspheres is more effective on overall survival in advanced Hepatocellular carcinoma (HCC) with or without portal venous obstruction and no extrahepatic extension than sorafenib which is now the standard treatment of advanced HCC.

ReferenceCitation: Zarca K, Mimouni M, Pereira H, Chatellier G, Vilgrain V, Durand-Zaleski I; SARAH Trial Group. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clin Ther. 2021 Jul;43(7):1201-1212. doi: 10.1016/j.clinthera.2021.04.018. Epub 2021 May 28.

family: Zarca

full_name: Kevin Zarca

given: Kevin

family: Mimouni

full_name: Maroua Mimouni

given: Maroua

family: Pereira

full_name: Helena Pereira

given: Helena

family: Chatellier

full_name: Gilles Chatellier

given: Gilles

family: Vilgrain

full_name: Valérie Vilgrain

given: Valérie

family: Durand-Zaleski

full_name: Isabelle Durand-Zaleski

given: Isabelle

journal_name: Clinical Therapeutics

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

ReferenceCitation: Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with (90)Y in the SARAH Study. Radiology. 2020 Sep;296(3):673-684. doi: 10.1148/radiol.2020191606. Epub 2020 Jun 30.

family: Hermann

full_name: Anne-Laure Hermann

given: Anne-Laure

family: Dieudonné

full_name: Arnaud Dieudonné

given: Arnaud

family: Ronot

full_name: Maxime Ronot

given: Maxime

family: Sanchez

full_name: Manuel Sanchez

given: Manuel

family: Garin

full_name: Etienne Garin

given: Etienne

family: Castera

full_name: Laurent Castera

family: Lebtahi

full_name: Rachida Lebtahi

given: Rachida

journal_name: Radiology

publisher: Radiological Society of North America (RSNA)

title: Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study

ReferenceCitation: Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.

family: Assenat

full_name: Eric Assenat

given: Eric

ReferenceCitation: Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.

repository_institution: 4 institutions : Université de Strasbourg, Université de Haute Alsace, INSA Strasbourg, Bibliothèque Nationale et Universitaire de Strasbourg - univOAK

title: Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial

location_facility:
Hôpital Haut Leveque #14
CHU Grenoble #5
Henri Mondor #24
Paul Brousse #19
Hôpital Antoine Béclère #29
Hôpital Edouard Herriot #6
CHU Amiens #2
Hôpital de L'Archet #11
Hopital beaujon #1
CHRU Besançon Hôpital Jean Minjoz #21
Hôpital Jean Verdier #25
Hotel Dieu #10
Institut Gustave Roussy #20
Hôpital Côte de Nacre #4
CHU Dijon Hôpital Bocage #22
Hôpital de Brabois #9
Hôpital de Hautepierre #18
CHU Marseille Hôpital La Timone #23
CHU Saint Etienne Hôpital Nord #17
Hôpital Saint Eloi #8
Hôpital Européen Georges Pompidou #13
Lyon La croix Rousse #27
CHU Robert Debré #28
Institut Paoli Calmettes #7
CHU Angers #3
CHU Poitiers La Milétrie


title: Medical and Economical Evaluation of Upper Limb's Rehabilitation Robotics After a Stroke

summary: Upper limb motor control after a stroke may be improved with rehabilitation robotics at a subacute stage. The aim of this multicenter controled randomized single blind study is to define the place of rehabilitation robotics at this phase of the rehabilitation process. Both groups will realize the same time of rehabilitation. The cost benefit ratio will be compared in each group through medical assessment of improvement and definition of the costs due to the rehabilitation process.

ReferenceCitation: Rémy-Néris O, Le Jeannic A, Dion A, Médée B, Nowak E, Poiroux É, Durand-Zaleski I; REM Investigative Team*. Additional, Mechanized Upper Limb Self-Rehabilitation in Patients With Subacute Stroke: The REM-AVC Randomized Trial. Stroke. 2021 Jun;52(6):1938-1947. doi: 10.1161/STROKEAHA.120.032545. Epub 2021 Apr 29.

name: Physical and Rehabilitation Medicine Department (O.R.-N., B.M., É.P.), Brest University Hospital, France.

name: Laboratory of Medical Information Processing, INSERM UMR 1101, Brest, France (O.R.-N., B.M.).

family: Rémy-Néris

full_name: Olivier Rémy-Néris

given: Olivier

name: Health Economics Clinical Research Unit (URC Eco), APHP, Paris, France (A.L.J., I.D.-Z.).

family: Le Jeannic

full_name: Anaïs Le Jeannic

given: Anaïs

name: INSERM, CIC 1412 (A.D., E.N.), Brest University Hospital, France.

family: Dion

full_name: Angelina Dion

given: Angelina

family: Médée

full_name: Béatrice Médée

given: Béatrice

family: Nowak

full_name: Emmanuel Nowak

given: Emmanuel

family: Poiroux

full_name: Élodie Poiroux

given: Élodie

family: Beis

full_name: Jean-Marie Beis

given: Jean-Marie

family: Bensmaïl

full_name: Djamel Bensmaïl

given: Djamel

family: Benaim

full_name: Charles Benaim

given: Charles

family: Luaute

full_name: Jacques Luaute

given: Jacques

family: Bonan

full_name: Isabelle Bonan

family: Boyer

full_name: François Boyer

given: François

family: Coudeyre

full_name: Emmanuel Coudeyre

family: Daviet

full_name: Jean-Christophe Daviet

given: Jean-Christophe

family: Dehail

full_name: Patrick Dehail

given: Patrick

family: Ferrapie

full_name: Anne-Laure Ferrapie

family: Isambert

full_name: Jean-Luc Isambert

given: Jean-Luc

family: Kerdraon

full_name: Jacques Kerdraon

family: Marque

full_name: Philippe Marque

given: Philippe

family: Froger

full_name: Jerome Froger

given: Jerome

family: Allart

full_name: Etienne Allart

family: Gross

full_name: Raphaël Gross

given: Raphaël

location_facility:
CHU d'Amiens
Centre Bouffard Vercelli
CHU de Clermont-Ferrand
CHU de Montpellier
CHRU de Brest
CHU de Rennes
CHU de Toulouse
APHP - Hôpital Lariboisière
IRR de Nancy
CHU de Bordeaux
CH de Garches
APHP - Hôpital La Salpétriere
CRF de Valmante
EMPR Le Normandy
CHU de Nîmes
CHU de Dijon
CHU de Nantes
CMRRF Kerpape
CRRRF
CHU de Reims
CHRU de Lille
CHU de Limoges
CHU de Lyon


title: Effects of Albumin Administration in Septic Cirrhotic Patients With Child > 8 Unrelated to Spontaneous Bacterial Peritonitis on Renal Function and Survival: A Multicenter Randomized Controlled Trial Comparing Use and Non-use of Human Albumin (Vialebex ®)

acronym: ALB-CIRINF

summary:
Patients with cirrhosis present an increased susceptibility to bacterial infections. Spontaneous bacterial peritonitis (SBP) is the most frequent infection and induces severe circulatory dysfunction associated with renal failure in about 30% of cases. Renal failure is a reliable surrogate marker of in-hospital mortality in patients with SBP or with non-SBP infections. Albumin, as an adjuvant to antibiotherapy reduces significantly the rate of renal failure, in-hospital mortality, and overall mortality (Sort P, et al. NEJM 1999). However, little is known regarding the effect of albumin administration in patients with non-SBP infections. Two recent prospective studies demonstrated that non-SBP infections are associated with impairment of the effective circulating volume and precipitate renal failure whatever the presence of ascites.

The aim of this randomized clinical trial is to evaluate the effects of albumin, associated with appropriate antibiotic therapy, on occurrence or deterioration of renal failure and survival in septic (SIRS criteria required) cirrhotic patients with non-SBP infections and presenting with a Child-Pugh score > 8.

status: Terminated

ReferenceCitation: Thévenot T, Bureau C, Oberti F, Anty R, Louvet A, Plessier A, Rudler M, Heurgué-Berlot A, Rosa I, Talbodec N, Dao T, Ozenne V, Carbonell N, Causse X, Goria O, Minello A, De Ledinghen V, Amathieu R, Barraud H, Nguyen-Khac E, Becker C, Paupard T, Botta-Fridlung D, Abdelli N, Guillemot F, Monnet E, Di Martino V. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol. 2015 Apr;62(4):822-30. doi: 10.1016/j.jhep.2014.11.017. Epub 2014 Nov 21.

family: Thévenot

full_name: Thierry Thévenot

given: Thierry

family: Bureau

full_name: Christophe Bureau

given: Christophe

family: Oberti

full_name: Frédéric Oberti

given: Frédéric

family: Anty

full_name: Rodolphe Anty

given: Rodolphe

family: Louvet

full_name: Alexandre Louvet

given: Alexandre

family: Plessier

full_name: Aurélie Plessier

given: Aurélie

family: Rudler

full_name: Marika Rudler

given: Marika

family: Heurgué-Berlot

full_name: Alexandra Heurgué-Berlot

given: Alexandra

family: Rosa

full_name: Isabelle Rosa

given: Isabelle

family: Talbodec

full_name: Nathalie Talbodec

given: Nathalie

family: Dao

full_name: Thong Dao

given: Thong

family: Ozenne

full_name: Violaine Ozenne

given: Violaine

family: Carbonell

full_name: Nicolas Carbonell

given: Nicolas

family: Causse

full_name: Xavier Causse

given: Xavier

family: Goria

full_name: Odile Goria

given: Odile

family: Minello

full_name: Anne Minello

given: Anne

family: De Ledinghen

full_name: Victor De Ledinghen

given: Victor

family: Amathieu

full_name: Roland Amathieu

given: Roland

family: Barraud

full_name: Hélène Barraud

given: Hélène

family: Nguyen-Khac

full_name: Eric Nguyen-Khac

given: Eric

family: Becker

full_name: Claire Becker

given: Claire

family: Paupard

full_name: Thierry Paupard

family: Botta-Fridlung

full_name: Danielle Botta-Fridlung

given: Danielle

lead_sponsor: Centre Hospitalier Universitaire de Besancon

location_facility: Centre Hospitalier régional Universitaire

location_facility: Centre Hospitalier Universitaire de Besançon


title: Pharmacoeconomic and Clinical Prospective Comparison of PET-scan and MRI in Patients With de Novo Multiple Myeloma Less Than 65 Years of Age Treated According to IFM/DFCI 2009 Clinical Trial.

acronym: IMAJEM

summary: Multicenter open-label prospective comparative study of PET-scan and MRI at the time of diagnosis, after 3 cycles of induction therapy (RVD) and at the completion of therapy.

ReferenceCitation: Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bodéré F. Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.

name: “Seragnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

family: Zamagni

full_name: Elena Zamagni

given: Elena

name: Nuclear Medicine, L’Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi, Bologna, Italy

family: Nanni

full_name: Cristina Nanni

given: Cristina

family: Dozza

full_name: Luca Dozza

given: Luca

name: Nuclear Medicine Department, Nantes University Hospital, CRCINA INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France

family: Carlier

full_name: Thomas Carlier

given: Thomas

family: Bailly

full_name: Clément Bailly

given: Clément

family: Tacchetti

full_name: Paola Tacchetti

given: Paola

name: Nuclear Medicine, AUSL-IRCSS of Reggio Emilia, Reggio Emilia, Italy

family: Versari

full_name: Annibale Versari

given: Annibale

name: Medical Physics Unit, Santa Croce e Carle Hospital, Cuneo, Italy

family: Chauvie

full_name: Stephane Chauvie

given: Stephane

name: Research and Innovation Department, Antoine Lacassagne Cancer Center, Nice, France

family: Gallamini

full_name: Andrea Gallamini

given: Andrea

name: Hematology Unit, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy

family: Gamberi

full_name: Barbara Gamberi

given: Barbara

name: Hematology Department, University Hospital, Dijon, France

family: Caillot

full_name: Denis Caillot

given: Denis

name: Hematology, Dipartimento di Area Medica, Udine University, Udine, Italy

family: Patriarca

full_name: Francesca Patriarca

given: Francesca

name: Hematology Department, University Hospital, Caen, France

family: Macro

full_name: Margaret Macro

given: Margaret

name: Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

family: Boccadoro

full_name: Mario Boccadoro

given: Mario

name: Hematology Department, University Hospital, Pitié Salpétriere, Paris, France

family: Garderet

full_name: Laurent Garderet

given: Laurent

family: Barbato

full_name: Simona Barbato

given: Simona

family: Fanti

full_name: Stefano Fanti

given: Stefano

name: Hematology Department, University Hospital, Nancy, France

family: Perrot

full_name: Aurore Perrot

given: Aurore

family: Gay

full_name: Francesca Gay

name: Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

family: Sonneveld

full_name: Peter Sonneveld

given: Peter

name: Hematology Department, University Hospital, Lyon, France

family: Karlin

full_name: Lionel Karlin

given: Lionel

family: Cavo

full_name: Michele Cavo

given: Michele

family: Bodet-Milin

full_name: Caroline Bodet-Milin

given: Caroline

name: Hematology Department, University Hospital, Nantes, France

publisher: American Society of Clinical Oncology (ASCO)

title: Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma

ReferenceCitation: Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, Moreau P, Touzeau C, Zamagni E, Bodet-Milin C, Kraeber-Bodéré F, Mateus D, Carlier T. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1005-1015. doi: 10.1007/s00259-020-05049-6. Epub 2020 Oct 2.

journal_name: European Journal of Nuclear Medicine and Molecular Imaging

location_facility: Lille University Hospital "Claude Huriez"

location_facility: Metz University Hospital "Hôpital de Mercy"

location_facility: Tours University Hospital "Hôpital Bretonneau"

location_facility: Brest University Hospital "CHU du Morvan"

location_facility: Grenoble University Hospital "Hôpital Michallon"

location_facility: Nancy University Hospita "Hôpitaux de Brabois"


title: Impact of Small Bowel Preparation Using Polyethylene Glycol for Endoscopic Video-capsule (EVC)Exploration in Unexplained Gastrointestinal Bleedings

acronym: PREPINTEST

summary: The best preparation of small bowel is still unknown. The primary aim of this study is to evaluate the polyethylene glycol (PEG) impact of small bowel preparation for unexplained gastrointestinal bleeding exploration. Three different preparations are evaluated in this study.

lead_sponsor: University Hospital, Brest

location_facility: Centre Hospitalier Universitaire de Nice


title: Evaluationof the Efficiency of a Resorbable Barrier Membrane for the Prevention of Abdominal and Peri-hepatic Adhesion in Patients With Colorectal Cancer Requiring Two-stage Surgery for the Resection of Hepatic Metastases

summary:
The purpose of this study is to evaluate the efficiency of a resorbable barrier membrane for the prevention of abdominal and peri-hepatic adhesion in patients with colorectal cancer requiring two-stage surgery for the resection of hepatic metastases.

Eligible patients will be randomly assigned to one of 2 arms:

Seprafilm group (receiving resorbable barrier membrane during the first surgery)
No-treatment control group (without seprafilm barrier during the first surgery)

The primary objective is to establish, in patients with colorectal cancer requiring two-stage surgery for the resection of hepatic metastases, the efficiency of a resorbable barrier membrane (Seprafilm) for limiting abdominal and peri-hepatic adhesion during the second operation.

This study is a prospective multicentric phase II, controlled, randomized and non comparative trial.

A total of 60 patients will be enrolled: 45 will receive Seprafilm whereas 15 will be assigned to the no-treatment control group. The inclusion period should be approximately 18 months. The follow up period after the second surgery will be 3 years.

ReferenceCitation: Weibel MA, Majno G. Peritoneal adhesions and their relation to abdominal surgery. A postmortem study. Am J Surg. 1973 Sep;126(3):345-53.

ReferenceCitation: Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg. 2000 Dec;232(6):777-85.

ReferenceCitation: Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51.

ReferenceCitation: Ellis H, Moran BJ, Thompson JN, Parker MC, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Brien F, Buchan S, Crowe AM. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet. 1999 May 1;353(9163):1476-80.

ReferenceCitation: Beck DE, Opelka FG, Bailey HR, Rauh SM, Pashos CL. Incidence of small-bowel obstruction and adhesiolysis after open colorectal and general surgery. Dis Colon Rectum. 1999 Feb;42(2):241-8. Erratum in: Dis Colon Rectum 1999 May;42(5):578.

ReferenceCitation: Diamond MP, Freeman ML. Clinical implications of postsurgical adhesions. Hum Reprod Update. 2001 Nov-Dec;7(6):567-76. Review.

ReferenceCitation: Ray NF, Denton WG, Thamer M, Henderson SC, Perry S. Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994. J Am Coll Surg. 1998 Jan;186(1):1-9.

ReferenceCitation: Lower AM, Hawthorn RJ, Ellis H, O'Brien F, Buchan S, Crowe AM. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study. BJOG. 2000 Jul;107(7):855-62.

ReferenceCitation: Lower AM, Hawthorn RJ, Clark D, Boyd JH, Finlayson AR, Knight AD, Crowe AM; Surgical and Clinical Research (SCAR) Group. Adhesion-related readmissions following gynaecological laparoscopy or laparotomy in Scotland: an epidemiological study of 24 046 patients. Hum Reprod. 2004 Aug;19(8):1877-85. Epub 2004 Jun 3.

ReferenceCitation: Parker MC, Ellis H, Moran BJ, Thompson JN, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Briena F, Buchan S, Crowe AM. Postoperative adhesions: ten-year follow-up of 12,584 patients undergoing lower abdominal surgery. Dis Colon Rectum. 2001 Jun;44(6):822-29; discussion 829-30.

ReferenceCitation: Parker MC. Epidemiology of adhesions: the burden. Hosp Med. 2004 Jun;65(6):330-6. Review.

ReferenceCitation: Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005 Nov;99(2):301-8. Epub 2005 Aug 8.

ReferenceCitation: Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Peeler ST. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol. 2007 Mar;104(3):739-46. Epub 2006 Nov 13.

ReferenceCitation: Duron JJ. [Post-operative bowel obstruction. Part 2: Mechanical post-operative small bowel obstruction by bands and adhesions]. J Chir (Paris). 2003 Dec;140(6):325-34. Review. French.

ReferenceCitation: Duron JJ. [Post-operative bowel obstruction. Part 1: Intraperitoneal bands and adhesions--causes and prevention]. J Chir (Paris). 2003 Sep;140(4):211-9. Review. French.

ReferenceCitation: Cuervas-Mons V, Rimola A, Van Thiel DH, Gavaler JS, Schade RR, Starzl TE. Does previous abdominal surgery alter the outcome of pediatric patients subjected to orthotopic liver transplantation? Gastroenterology. 1986 Apr;90(4):853-7.

ReferenceCitation: Sandler AD, Azarow KS, Superina RA. The impact of a previous Kasai procedure on liver transplantation for biliary atresia. J Pediatr Surg. 1997 Mar;32(3):416-9.

ReferenceCitation: Ong TH. Prevention of intraabdominal adhesions in Kasai portoenterostomy. J Pediatr Surg. 2001 Nov;36(11):1613-4.

ReferenceCitation: Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P, Nordlinger B. Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br J Surg. 1997 Jul;84(7):977-80.

ReferenceCitation: Rivoire M; ANAES. [Can initially non-respectable hepatic metastases be made resectable?]. Gastroenterol Clin Biol. 2003 Mar;27 Spec No 2:B18-9, B88-104. French.

ReferenceCitation: Al-Jaroudi D, Tulandi T. Adhesion prevention in gynecologic surgery. Obstet Gynecol Surv. 2004 May;59(5):360-7. Review.

ReferenceCitation: Beck DE, Cohen Z, Fleshman JW, Kaufman HS, van Goor H, Wolff BG; Adhesion Study Group Steering Committee. A prospective, randomized, multicenter, controlled study of the safety of Seprafilm adhesion barrier in abdominopelvic surgery of the intestine. Dis Colon Rectum. 2003 Oct;46(10):1310-9.

ReferenceCitation: Becker JM, Dayton MT, Fazio VW, Beck DE, Stryker SJ, Wexner SD, Wolff BG, Roberts PL, Smith LE, Sweeney SA, Moore M. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996 Oct;183(4):297-306.

ReferenceCitation: Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril. 1996 Dec;66(6):904-10.

ReferenceCitation: Salum MR, Lam DT, Wexner SD, Pikarsky A, Baig MK, Weiss EG, Nogueras JJ, Singh JJ. Does limited placement of bioresorbable membrane of modified sodium hyaluronate and carboxymethylcellulose (Seprafilm) have possible short-term beneficial impact? Dis Colon Rectum. 2001 May;44(5):706-12.

ReferenceCitation: Tang CL, Seow-Choen F, Fook-Chong S, Eu KW. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision: a prospective, randomized trial. Dis Colon Rectum. 2003 Sep;46(9):1200-7.

ReferenceCitation: Vrijland WW, Tseng LN, Eijkman HJ, Hop WC, Jakimowicz JJ, Leguit P, Stassen LP, Swank DJ, Haverlag R, Bonjer HJ, Jeekel H. Fewer intraperitoneal adhesions with use of hyaluronic acid-carboxymethylcellulose membrane: a randomized clinical trial. Ann Surg. 2002 Feb;235(2):193-9.

ReferenceCitation: Tingstedt B, Isaksson K, Andersson E, Andersson R. Prevention of abdominal adhesions--present state and what's beyond the horizon? Eur Surg Res. 2007;39(5):259-68. Epub 2007 May 10. Review.

ReferenceCitation: Oikonomakis I, Wexner SD, Gervaz P, You SY, Secic M, Giamundo P. Seprafilm: a retrospective preliminary evaluation of the impact on short-term oncologic outcome in colorectal cancer. Dis Colon Rectum. 2002 Oct;45(10):1376-80.

ReferenceCitation: Kusunoki M, Ikeuchi H, Yanagi H, Noda M, Tonouchi H, Mohri Y, Uchida K, Inoue Y, Kobayashi M, Miki C, Yamamura T. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today. 2005;35(11):940-5.

ReferenceCitation: Wieand HS. Randomized phase II trials: what does randomization gain? J Clin Oncol. 2005 Mar 20;23(9):1794-5. Epub 2005 Feb 7.

ReferenceCitation: Dixon WJ, Massey FJ. Introduction to statistical analysis. 4th Edition McGraw-Hill, 1983; 80-5.

ReferenceCitation: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.

ReferenceCitation: Dupré A, Lefranc A, Buc E, Delpero JR, Quenet F, Passot G, Evrard S, Rivoire M. Use of bioresorbable membranes to reduce abdominal and perihepatic adhesions in 2-stage hepatectomy of liver metastases from colorectal cancer: results of a prospective, randomized controlled phase II trial. Ann Surg. 2013 Jul;258(1):30-6. doi: 10.1097/SLA.0b013e3182854949.

family: Dupré

full_name: Aurélien Dupré

given: Aurélien

family: Lefranc

full_name: Anne Lefranc

given: Anne

family: Buc

full_name: Emmanuel Buc

given: Emmanuel

family: Delpero

full_name: Jean Robert Delpero

given: Jean Robert

family: Quenet

full_name: François Quenet

given: François

family: Passot

full_name: Guillaume Passot

given: Guillaume

family: Evrard

full_name: Serge Evrard

given: Serge

family: Rivoire

full_name: Michel Rivoire

given: Michel

journal_name: Annals of Surgery

title: Use of Bioresorbable Membranes to Reduce Abdominal and Perihepatic Adhesions in 2-Stage Hepatectomy of Liver Metastases From Colorectal Cancer

lead_sponsor: Centre Leon Berard

location_facility:
Centre Léon Bérard
Centre Alexis Vautrin
Hôpital Charles Nicolle - CHU Rouen
CHU Clermont Ferrand
Hôpital de Brabois CHU
Centre Hospitalier Lyon Sud
CHU La conception
Hôpital Antoine Béclère
Hôpital Cochin
Institut Paoli Calmettes
CHU Grenoble
Hôpital de La Croix Rousse
Institut Bergonié
Centre Val d'Aurelle Paul Lamarque
Institut Gustave Roussy
CHU Nice-Hôpital de l'Archet II
Hôpital Beaujon


title: Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliativecare Unit - Etude RHESO - Etude Monocentrique

acronym: RHESO

summary: Even if most patients in palliative care units presented with well-recognized risks factors of venous thromboembolism (VTE) (eg: active cancer, bed rest, previous history of venous thrombosis), the incidence of VTE in palliative setting is unknown. By consequence, the efficacy and safety of antithrombotic prophylaxis in such a population is not established. Indeed, patients admitted in palliative care units were not included in trials evaluating the potential effect of antithrombotic drugs in regard to their poor prognosis at short term. In addition, the main role of prophylaxis is to prevent sudden death from pulmonary emboli and is thus a life prolonging therapy which is viewed as counterintuitive to palliative care philosophy and inappropriate on grounds of futility. Nevertheless, the current use of Low Molecular Weight Heparin in palliative care units seems to increase particularly in patients with advanced malignancy. The identification of high hemorrhagic risks in palliative care patients could help the decision of antithrombotic prophylaxis initiation. For this, the investigators conducted a multicenter prospective longitudinal study.

location_facility: Hôpital Joseph Ducuing - CH Saint-Gaudens


title: Evaluation of the " Tele-follow-up " for the Follow-up of Implantable Defibrillators

acronym: EVATEL

summary:
The implantable cardioverter defibrillator (ICD) has been shown to be effective in preventing mortality in patients with ventricular tachyarrhythmia. However, the expanding indications of this therapy will have an impact on the follow-up policy. Currently, regular follow-up visits are scheduled every 3 months. In this context, the recently-introduced "remote monitoring" devices constitute a promising new technique, allowing to transmit information about the status of the device and ICD therapies, without direct contact between patients and physicians. This monitoring by "tele-follow-up" might reduce the cost of care by avoiding useless visits to the implantation centre.

The aim of our study is to assess the cost-benefit ratio of "tele-follow-up" assisted care as compared with the conventional ICD follow-up.

lead_sponsor: Rennes University Hospital

location_facility: Service de Cardiologie - CHU de Clermont-Ferrand

location_facility: Service de Cardiologie - Hôpital Européen Georges Pompidou

location_facility: Hôpital Cardiologique du Haut Lévêque - CHU de Bordeaux

location_facility: Service de Cardiologie - Centre Hospitalier du Pays d'Aix

location_facility: Département de Cardiologie - CHU de Reims

location_facility: Département de Cardiologie et Maladies Vasculaires - Hôpital de Pontchaillou

location_facility: Service de Cardiologie - Hôpital de la Côte de Nacre

location_facility: Service de Cardiologie - Institut du Thorax - Hôpital Laennec

location_facility: Service de Cardiologie - CHU Jean Minjoz

location_facility: Service de Cardiologie - Groupement Hospitalier Est de Lyon

location_facility: Service de Chirurgie Cardiovasculaire - Hôpital Rangueil

location_facility: Service de Cardiologie B - Hôpital Trousseau

location_facility: Service de Cardiologie - Hôpital Charles Nicolle

location_facility: Service de Cardiologie - Hôpital de Hautepierre

location_facility: Service de Cardiologie - CHU Timone Adultes

location_facility: Service de Cardiologie -Hôpital de la Cavale Blanche

location_facility: Service de Cardiologie - Hôpital Pasteur

location_facility: Service de Cardiologie - CHU de Saint Etienne

location_facility: Service de cardiologie et Urgences cardiologiques - Hôpital Michallon

location_facility: Service de Cardiologie - Hôpital Henri Mondor

location_facility: Service médico-chirurgical de Cardiologie - CHU de Poitiers

location_facility: Département de Cardiologie - CHU de Montpellier

location_facility: Département de Cardiologie - CHU de Nancy-Brabois

location_facility: Service de Cardiologie - Hôpital Lariboisière

location_facility: Institut de Cardiologie - Hôpital de la Pitité Salpétrière


title: Comparison of Two Strategies for Setting Positive End-Expiratory Pressure in Acute Lung Injury/ Acute Respiratory Distress Syndrome (ExPress Study).

acronym: ExPress

summary: The aim of this multicenter randomized controlled trial is to compare the impact on mortality of patients mechanically ventilated for acute lung injury or acute respiratory distress syndrome of two strategies for setting end-expiratory pressure.

ReferenceType: result

ReferenceCitation: Mercat A, Richard J, Brochard L. Comparison of two strategies for setting Peep in ALI/ARDS : EsPress Study.Intensive care med, 19th ESICM Annual Congress - Barcelona, Spain, 2006 Sep, Oral presentation 0365

ReferenceCitation: Diehl JL, Coolen N, Faisy C, Osman D, Prat G, Sebbane M, Nieszkowska A, Gervais C, Richard JC, Richecoeur J, Brochard L, Mercat A, Guérot E, Borgel D. Growth-arrest-specific 6 (GAS6) protein in ARDS patients: determination of plasma levels and influence of PEEP setting. Respir Care. 2013 Nov;58(11):1886-91. doi: 10.4187/respcare.02129. Epub 2013 Apr 9.

family: Diehl

full_name: J.-L. Diehl

family: Coolen

full_name: N. Coolen

given: N.

family: Faisy

full_name: C. Faisy

given: C.

family: Osman

full_name: D. Osman

given: D.

family: Prat

full_name: G. Prat

given: G.

family: Sebbane

full_name: M. Sebbane

given: M.

family: Nieszkowska

full_name: A. Nieszkowska

given: A.

family: Gervais

full_name: C. Gervais

family: Richard

full_name: J.-C. M. Richard

family: Richecoeur

full_name: J. Richecoeur

given: J.

family: Brochard

full_name: L. Brochard

given: L.

family: Mercat

full_name: A. Mercat

family: Guerot

full_name: E. Guerot

given: E.

family: Borgel

full_name: D. Borgel

journal_name: Respiratory Care

oa_colors: green other

evidence: oa repository (via OAI-PMH title and last author match)

repository_institution: The Pennsylvania State University - CiteSeer X

repository_normalized: CiteSeerX

publisher: Daedalus Enterprises

publisher_dissemination: Daedalus Enterprises

publisher_group: Daedalus Enterprises

publisher_normalized: Daedalus Enterprises

title: Growth-Arrest-Specific 6 (GAS6) Protein in ARDS Patients: Determination of Plasma Levels and Influence of PEEP Setting

ReferenceCitation: Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L; Expiratory Pressure (Express) Study Group. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008 Feb 13;299(6):646-55. doi: 10.1001/jama.299.6.646.

full_name: Alain Mercat

given: Alain

full_name: Jean-Christophe M. Richard

given: Jean-Christophe M.

family: Vielle

full_name: Bruno Vielle

given: Bruno

family: Jaber

full_name: Samir Jaber

given: Samir

full_name: for the Expiratory Pressure (Express) Study Group

title: Positive End-Expiratory Pressure Setting in Adults With Acute Lung Injury and Acute Respiratory Distress Syndrome

location_facility:
General Hospital of Avignon
Saint Eloi Hospital
University Hospital of Jean Bernard
Henri Mondor Hospital
European Hospital of Georges Pompidou
Saint André Hospital
General Hospital of Aix en Provence
René Dubos Hospital
Le Kremlin Bicetre Hospital
Hospital Group of Pitié - Salpêtrière
University Hospital of La Milètrie
Bon Secours Hospital
Hospital of Dieppe
University Hospital of Amiens
University Hospital of Claude Huriez
University Hospital of Hotel Dieu
Oloron Sainte Marie Hospital
University Hospital of Hôtel Dieu
Departemental Hospital
Hospital group of Pitié-Salpêtrière
Hospital of Soissons
Hautepierre Hospital
University Hospital of Nimes
Regional Hospital of Orleans
Hospital of Beauvais
University Hospital of Angers
Jacques Monod Hospital
Victor Dupouy Hospital
Hospital of Dax
Charles Nicolle Hospital
Hospital of Brive
Gustave Dron Hospital
General Hospital of Arras
University Hospital of Rouen
Robert Ballanger Hospital
Hospital of Nancy
Croix Rousse Hospital
University Hospital of Bordeaux
Saint Aubin Les Elbeuf Hospital
South Hospital of Amiens
University Hospital of Bellevue
Docteur Schaffner Hospital
Bichat Claude Bernard Hospital
Cavale Blanche Hospital


title: Strategies for Suspected Pulmonary Embolism in Emergency Departments - SPEED Study

summary:
Aims: 1) To evaluate the effectiveness of two interventions aimed at improving the management of patients with suspected pulmonary embolism: Written guidelines and Computer-Assisted Decision Support (CADS). 2) To evaluate the impact of electronic reminders on the appropriateness of the treatment of patients with suspected PE

Design: Pragmatic, unblinded, cluster randomised controlled study.

Setting: 20 French Emergency Departments

Patients: Out patients suspected of having pulmonary embolism

Methods: Emergency physicians will prospectively complete a standardized electronic form on Personal Data Assistant (PDA), including patients' characteristics, the clinical probability if assessed, the diagnostic tests performed, the treatments initiated and the final diagnostic and therapeutic decisions. Patients will be interviewed at the end of a 3-month follow-up period using a standardized questionnaire.

The reference rate of appropriateness of the diagnostic management before intervention will be assessed in each centre. At the end of this preliminary period, the centres will be randomized in two fold two groups according to a factorial design with stratification on their reference level of appropriateness. Half of the centres will have written guidelines and half a Computer-Assisted Decision Support for the diagnosis of PE on the PDA. In each of these two main groups, half of the centres will have electronic reminders on their PDA concerning the treatment of PE.

Judgment criteria

Main : Rate of strategies considered as validated according to the results of the systematic review and meta-analysis.3

Secondary judgment criteria (diagnosis):

Rate of strategies considered as validated or acceptable according to the opinion of international advisors.
Rate of thromboembolic-events during a 3-month follow-up period in patients for whom pulmonary embolism will be ruled out
Costs of the diagnostic management

Secondary judgment criteria (treatment):

Delay between Emergency Department admission and the first dose of antithrombotic treatment in patients with high clinical probability of PE according to the Revised Geneva Score
Rate of inappropriate treatment according to international recommendations for patients with confirmed PE.

Number of patients: By estimating that the rate of appropriateness would be 55% in the "written guidelines" group, 1331 patients are necessary to highlight an absolute superiority of 15% in the "CADS" group (rate of conformity of 70%).

The number of patients will be adjusted at the end of the preliminary period according to the level of appropriateness before interventions considering that it will improve less than 5% in the "written guidelines" group.

ReferenceCitation: Roy PM, Colombet I, Durieux P, Chatellier G, Sors H, Meyer G. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ. 2005 Jul 30;331(7511):259. Review.

ReferenceCitation: Roy PM, Durieux P, Gillaizeau F, Legall C, Armand-Perroux A, Martino L, Hachelaf M, Dubart AE, Schmidt J, Cristiano M, Chretien JM, Perrier A, Meyer G. A computerized handheld decision-support system to improve pulmonary embolism diagnosis: a randomized trial. Ann Intern Med. 2009 Nov 17;151(10):677-86. doi: 10.7326/0003-4819-151-10-200911170-00003.

family: Roy

full_name: Pierre-Marie Roy

given: Pierre-Marie

journal_name: Annals of Internal Medicine

publisher: American College of Physicians

publisher_dissemination: American College of Physicians

publisher_group: American College of Physicians

publisher_normalized: American College of Physicians

title: A Computerized Handheld Decision-Support System to Improve Pulmonary Embolism Diagnosis

lead_sponsor: University Hospital, Angers

location_facility:
UH Dijon
H le Mans
UH Nancy
UH La Pitie Salpetriere
H Argenteuil
UH Grenoble
H Chalons en Champagne
H Langres
H Lons le Saunier
H Roanne
UH Ambroise Pare
H Compiegne
UH Toulouse
H Saint Nazaire
H Thouars
UH Besançon
UH Caen
H Chateauroux
H Bethune
H Dreux


title: Rituximab Therapy in Anti-MAG Patients With Characteristics of Good Responders:

acronym: THERAMAG

summary: Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).

study_start_date_type: Anticipated

status: Not yet recruiting

location_facility:
CHU Tours - Bretonneau
CHU de Saint-Etienne
APHP - Kremlin-Bicêtre
HCL lyon
APHP Pitié Salpêtrière
CHU Strasbourg - Hautepierre
CHU Nice - Pasteur
CHU Brest - La cavale blanche
CHU Lille - Roger Salengro
CHU Limoges - Dupuytren
CHU Nancy- Hôpital central
CHU Toulouse - Pierre-Paul Riquet
CHU Grenoble - La tronche
CHU La Timone - APHM


title: Cost-utility Analysis of Ambulatory Care Compared to Conventional Patient Care of Permanent Pacemakers Replacement for Elective Replacement Indicator

acronym: START

summary:
START study is a comparison of cost-utility between permanent pacemaker replacement ambulatory care and permanent pacemaker replacement conventional hospitalization care.

The hypothesis of the study is that ambulatory care compared to conventional hospitalization, involving a stay of more than 24 hours, would reduce hospitalization and care expenses without loss of quality of care and without increasing the complication rate for patients.

location_facility:
AP-HM
Montpellier University Hospital
Strasbourg University Hospital
Lyon University Hospital
Brest University Hospital
Dijon University Hospital
Rennes University Hospital
Grenoble University Hospital
Nancy University Hospital
AP-HP, La Pitié Salpétrière
Angers University Hospital
Saint-Etienne University Hospital
Toulouse University Hospital
Tours University Hopsital


title: Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

acronym: FAIR-ALS II

summary: The alteration of iron metabolism is reported in animal models of amyotrophic lateral sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS. The high iron concentration of the brain, due to its high energy demand (high oxygen consumption), makes motor neurons particularly vulnerable to energy deficit and oxidative stress. Post-mortem examinations and MRI scans in patients with ALS have found signs of iron accumulation in the central motor tract; and a high level of serum ferritin, which is a marker of iron levels, is associated with a lower prognosis. In ALS mouse models, the use of iron chelators has demonstrated neuroprotection and increased life expectancy, suggesting that elimination of excess iron from the brain can prevent neuronal loss and, consequently, a slow progression of the disease. Conservative chelation of iron refers to a modality whereby much of the iron that binds to the chelator is redistributed in the body rather than exhausted. Using a chelator, deferiprone, with this feature, in a safety pilot study, a very good safety profile was observed. Deferiprone eliminated excess iron from brain regions, reduced oxidative damage and cell death associated with regional iron deposits with no apparent negative impact on the iron levels needed. Now, the efficacy of this new therapeutic modality of neuroprotection is being evaluated in a randomized, double-blind, placebo-controlled, multicenter study.

location_facility:
Hôpital Roger Salengro, CHU
Chr Angers
Chru Brest
Hopital Pierre Wertheimer - Hcl - Bron
Chu de Bordeaux - Talence
Chu de Tours
Chu de Clermont-Ferrand
Hopital de Hautepierre
Hu Pitie Salpetriere Aphp
Chu Toulouse
Chu de Nice Hopital Pasteur
C H U Dupuytren Limoges
Chu de Nancy
Chu Cote de Nacre - Caen
Aphm Hopital La Timone


title: Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery Using Conventional Blood Coagulation Tests or Thrombo-elastographic Point of Care Test - IMOTEC

acronym: IMOTEC

summary:
Peri operative haemorrhage following cardio Pulmonary Bypass may occur in 5 to 10% of cardiac surgical interventions.

Treatment of such complication often necessitates various combinations therapeutic intervention including allogenic blood products administration, drug use and/or surgical intervention. All are expensive treatment and decision making is guided by patient clinical status and biological tests of the haemostatic function.

A key point is the time frame of the clinical process. Therapeutic choices have to be done as fast as possible to minimize bleeding consequences on patient haemodynamic and physiological status. Conventional coagulation test results availability time usually exceed 45' after blood drawing. In such situation, the results may not reflect precisely the coagulation system current state. This downside is often counterbalanced by clinicians empirical choices preceding lab test results knowledge that may conduct to inappropriate treatment, blood product overuse and undue expense.

Viscoelastic point of care test may compensate for the limitations of conventional coagulation tests. In perioperative haemorrhage, faster and more precise information about haemostatic function may help for more accurate therapeutic choices.

The IMOTEC study aims to compare haemorrhage management following cardiac surgery using conventional blood coagulation tests or thrombo-elastogaphic point of care test.

Primary endpoint is a cost utility analysis of the technology and secondary endpoints include blood component transfusion, postoperative bleeding , thoracic re-intervention, postoperative infection (any cause), organ failure, in hospital length of stay and death.

ReferenceCitation: Rigal JC, Boissier E, Lakhal K, Riche VP, Durand-Zaleski I, Rozec B. Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-wedge cluster randomised controlled design and 1-year follow-up (the IMOTEC study). BMJ Open. 2019 Nov 5;9(11):e029751. doi: 10.1136/bmjopen-2019-029751.

location_facility:
Bordeaux University hospital
Clermont-Ferrand University Hospital
Dijon University Hospital
Nancy University Hospital
Marseille AP-HM La Timone
Rouen University Hospital
Tours University Hospital
HEGP, Hôpital Européen Georges Pompidou
Strasbourg Universtiy Hospital
Toulouse University Hospital
Caen University Hospital
Angers University Hospital
Saint-Etienne University Hospital
APHP, La Pitié Salpétrière
Lille University hospital